370 related articles for article (PubMed ID: 8944008)
1. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
Ciardiello F; Damiano V; Bianco R; Bianco C; Fontanini G; De Laurentiis M; De Placido S; Mendelsohn J; Bianco AR; Tortora G
J Natl Cancer Inst; 1996 Dec; 88(23):1770-6. PubMed ID: 8944008
[TBL] [Abstract][Full Text] [Related]
2. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.
Ciardiello F; Tortora G
Clin Cancer Res; 1998 Apr; 4(4):821-8. PubMed ID: 9563874
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
[TBL] [Abstract][Full Text] [Related]
4. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
[TBL] [Abstract][Full Text] [Related]
6. Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells.
Ciardiello F; Damiano V; Bianco C; di Isernia G; Ruggiero A; Caraglia M; Tagliaferri P; Baselga J; Mendelsohn J; Bianco AR
Clin Cancer Res; 1995 Feb; 1(2):161-7. PubMed ID: 9815969
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
9. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.
Normanno N; Tortora G; De Luca A; Pomatico G; Casamassimi A; Agrawal S; Mendelsohn J; Bianco AR; Ciardiello F
Oncol Rep; 1999; 6(5):1105-9. PubMed ID: 10425310
[TBL] [Abstract][Full Text] [Related]
10. 8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer.
Bianco C; Tortora G; Baldassarre G; Caputo R; Fontanini G; Chinè S; Bianco AR; Ciardiello F
Clin Cancer Res; 1997 Mar; 3(3):439-48. PubMed ID: 9815703
[TBL] [Abstract][Full Text] [Related]
11. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
12. The epidermal growth factor receptor as a target for cancer therapy.
Mendelsohn J
Endocr Relat Cancer; 2001 Mar; 8(1):3-9. PubMed ID: 11350723
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human pancreatic cancer cell (MIA PaCa-2) growth by cholera toxin and 8-chloro-cAMP in vitro.
Ohmura E; Wakai K; Isozaki O; Murakami H; Onoda N; Emoto N; Shizume K; Tsushima T; Demura H; Robins RK
Br J Cancer; 1993 Feb; 67(2):279-83. PubMed ID: 8381655
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
18. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
20. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Eller JL; Longo SL; Hicklin DJ; Canute GW
Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
